Emerging treatment options for patients with castration-resistant prostate cancer.
about
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesRadium-223 dichloride in clinical practice: a review.Cell-cycle-dependent regulation of androgen receptor functionAngiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells.Targeted α-particle therapy of bone metastases in prostate cancerSrc controls castration recurrence of CWR22 prostate cancer xenografts.Caspase control: protagonists of cancer cell apoptosis.Chemotherapeutic inhibitors in the treatment of prostate cancer.Copper signaling axis as a target for prostate cancer therapeutics.Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cellsA transgenic mouse model for early prostate metastasis to lymph nodes.The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.Role of androgen receptor splice variants in prostate cancer metastasis.
P2860
Q26866135-A291FCBD-3580-4E79-82DE-CDFA90F2C5A0Q30251496-037C031C-B990-45B9-ACD3-CF821A1CBCAAQ30300725-E5E31DF0-7A12-4B1E-B525-E62FE28D6E00Q34238619-83B312A8-ACAE-4311-BAEB-A762ECD27FB3Q34495274-7D2E470F-E81D-43BD-B328-816D2269082EQ36029539-37C8C00B-BABE-4C4F-8BE7-D5F83F60B428Q36751712-AB600A5B-EC55-4B04-8706-E82F4DC93355Q37139643-D9FAE698-0351-4841-B44B-F729AA035045Q37417656-E1B70E29-B690-4B4B-8858-5DE73DCF97D4Q37481145-6DF5C3BA-6A94-4106-8DC4-9112CCA052EDQ38052382-B4F3A50B-A078-4F50-BA86-B1508E1633E9Q38155239-FD7B94B9-848B-4449-9AC4-E942EFBF8D88Q38947366-01DBD9CF-88DF-44F4-BCAC-3C63819F35D0Q39150333-EE603C9A-838E-4BB9-B2E4-7CB944BCE3A0Q41864582-7A9494D9-4CED-44C0-9C50-823076057761Q42417359-1FF3B315-48F7-4833-88F1-A78C1FD4FA4AQ53749556-461BEE2D-745A-4189-BB94-D5E02FC3C17A
P2860
Emerging treatment options for patients with castration-resistant prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Emerging treatment options for patients with castration-resistant prostate cancer.
@ast
Emerging treatment options for patients with castration-resistant prostate cancer.
@en
type
label
Emerging treatment options for patients with castration-resistant prostate cancer.
@ast
Emerging treatment options for patients with castration-resistant prostate cancer.
@en
prefLabel
Emerging treatment options for patients with castration-resistant prostate cancer.
@ast
Emerging treatment options for patients with castration-resistant prostate cancer.
@en
P2860
P356
P1433
P1476
Emerging treatment options for patients with castration-resistant prostate cancer.
@en
P2093
Daniel George
Judd W Moul
P2860
P304
P356
10.1002/PROS.21435
P577
2011-07-11T00:00:00Z